These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 11365016)

  • 41. Delavirdine gets FDA approval. Food and Drug Administration.
    AIDS Alert; 1997 Jun; 12(6):70. PubMed ID: 11364363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FDA approves 2 new protease inhibitors: ritonavir (Norvir) and Crixivan (Indinavir sulfate). Food and Drug Administration.
    Schouten JT
    STEP Perspect; 1996; 8(1):7-8. PubMed ID: 11363592
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Man of the Year. Hope with an asterisk.
    Lacayo R
    Time; 1996 Dec 30-1997 Jan 6; 148(29):82-5. PubMed ID: 10163846
    [No Abstract]   [Full Text] [Related]  

  • 44. New questions about an old combination--ddI + d4T.
    Proj Inf Perspect; 2003 Jan; (35):13-4. PubMed ID: 12647675
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Virologic failure and salvage therapy.
    HIV Hotline; 1998 Mar; 8(1):2-3. PubMed ID: 11365357
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV drug now approved for use with protease inhibitors.
    Nurse Pract; 1998 Oct; 23(10):89. PubMed ID: 9805335
    [No Abstract]   [Full Text] [Related]  

  • 47. Improvement in CD4+ cell counts despite persistently detectable HIV load.
    Levitz SM
    N Engl J Med; 1998 Apr; 338(15):1074-5. PubMed ID: 9537882
    [No Abstract]   [Full Text] [Related]  

  • 48. Understanding the reverse transcriptase inhibitors in HIV.
    Edmonds-Ogbuokiri J
    Fac Notes (New Orleans La); 1998; 10(6):13-5. PubMed ID: 11366142
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hybrid protocols.
    Posit Health News; 1998; (No 17):18-9. PubMed ID: 11366546
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FDA advisory committee deadlocks on delavirdine. Food and Drug Administration.
    Mascolini M
    AIDS Treat News; 1996 Dec; (No 260):3-5. PubMed ID: 11364022
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
    Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
    Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV therapeutics, continued: another HIV protease inhibitor approved.
    Laurence J
    AIDS Read; 2003 Aug; 13(8):355-6. PubMed ID: 14524318
    [No Abstract]   [Full Text] [Related]  

  • 53. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
    Moolasart P; Likanonsakul S
    Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):280-7. PubMed ID: 12236426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rescue me.
    Simmons P
    Res Initiat Treat Action; 1998 Aug; 4(5):10. PubMed ID: 11365705
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
    MMW Fortschr Med; 2003 Dec; 145(50):60-1. PubMed ID: 14963980
    [No Abstract]   [Full Text] [Related]  

  • 57. Bridging the gap. Bringing new antiretroviral medications into the clinic.
    Williams A
    Adv Nurse Pract; 1999 Jan; 7(1):24-30; quiz 31-2. PubMed ID: 10030167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug research shows easier dosing, new combinations are making gains.
    AIDS Alert; 1998 Apr; 13(4):37-9. PubMed ID: 11365139
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Strategies for protease inhibitor failure.
    Proj Inf Perspect; 1997 Nov; (23):4-5. PubMed ID: 11365379
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.